以嶺藥業(002603.SZ):卡託普利片通過一致性評價
格隆匯2月28日丨以嶺藥業(002603.SZ)公佈,近日,公司收到國家藥品監督管理局核准簽發的卡託普利片的《藥品補充申請批件》,該藥品通過仿製藥質量和療效一致性評價。
卡託普利片為血管緊張素轉移酶抑制藥,臨牀適應症為高血壓、心力衰竭,適應人羣廣,屬於國家醫保目錄甲類品種(2019年版)和基本藥物目錄品種(2018年版)。目前國內共有7個品規通過卡託普利片一致性評價。
根據國家相關政策規定,對於通過一致性評價的藥品品種,在醫保支付方面予以適當支持;醫療機構應優先採購併在臨牀中優先選用;同時,通過一致性評價的產品將具備參加國家藥品集中採購的資格。該品種通過一致性評價,有利於擴大產品的市場銷售,提高市場競爭力,對公司的經營業績產生積極影響,併為公司進行中的其他產品一致性評價工作積累寶貴的經驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.